EXAS — Exact Sciences Corporation

Summary of Exact Sciences (EXAS) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Grew 20% year-over-year to $851 million, exceeding guidance by $43 million.
• Screening Revenue: Increased 22% year-over-year to $666 million.
• Precision Oncology Revenue: Rose 12% year-over-year to $183 million.
• Adjusted EBITDA: Reached $135 million, a 37% increase year-over-year, with margins expanding to 16%.
• Free Cash Flow: Improved to $190 million for the quarter, totaling $236 million year-to-date, a 270% increase year-over-year.
• Gross Margins: Non-GAAP gross margins were 71%, down 100 basis points due to care gap shipments.

2. Strategic Updates and Business Highlights

• Cologuard Performance: Strong brand awareness and commercial execution contributed to record screening numbers, with over 12,000 new providers ordering Cologuard for the first time.
• Cancerguard Launch: A multi-cancer early detection test was launched, with plans for direct-to-consumer marketing and integration into existing healthcare workflows.
• ExactNexus Platform: Continued investment in technology to enhance patient access and streamline screening processes.
• Care Gap Programs: Significant growth in care gap initiatives, with record orders and partnerships with major payers to improve screening rates.
• Oncotype DX Expansion: Continued international growth and positive momentum in Precision Oncology products.

3. Forward Guidance and Outlook

• Revenue Guidance: Full year 2025 revenue guidance raised to $3.22 billion - $3.235 billion, with screening revenue expected between $2.51 billion - $2.52 billion.
• Adjusted EBITDA Guidance: Increased to $470 million - $480 million for the full year, implying over 47% growth.
• 2026 Outlook: While specific guidance will be provided in the next earnings call, the company aims for a 15% compounded annual growth rate from 2022 to 2027.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: The decline in gross margins due to care gap shipments may continue to impact profitability in the short term.
• Competitive Landscape: Concerns regarding reimbursement strategies for Cancerguard in a competitive market, especially with other companies pursuing similar tests.
• Regulatory Risks: Ongoing uncertainties related to the Freenome licensing agreement and the timeline for FDA approvals could pose risks to future revenue streams.

5. Notable Q&A Insights

• Care Gap Programs: The team is optimistic about the continued strength of care gap programs, which are expected to contribute significantly to revenue, although they come with lower gross margins.
• Cologuard Plus Transition: Plans to sunset the original Cologuard test to focus on Cologuard Plus, which has demonstrated superior performance metrics.
• Freenome Partnership: Clarification on the timeline for pivotal data and FDA submissions, with the company maintaining exclusive marketing rights for the CRC blood test.
• Oncodetect and MRD Tests: While Oncodetect is not expected to be a material contributor in 2025, the company sees long-term potential, particularly in breast cancer, leveraging existing trust in Oncotype DX.

Overall, Exact Sciences reported a strong quarter with significant growth in revenue and cash flow, driven by effective commercial strategies and new product launches, while also navigating challenges related to margins and competitive pressures.